CORE Kidney

IgA Nephropathy

Omeros ARTEMIS - IgA Nephropathy

Drug name: OMS721

  • Phase 3, double-blind, placebo-controlled
  • Mechanism: the drug is an immunoglobulin G4 monoclonal antibody that binds to/inhibits mannan-binding lectin associated serine protease. Suppression of LP (lectin pathway) activation

Key inclusion criteria:

  • Age ≥ 18
  • eGFR ≥ 30
  • Proteinuria > 1g/24h

Exclusion:

  • Immunosuppressant/cytotoxic drugs/eculizumab treatment within 8 weeks prior to screening (unless given for indications other than IgAN)
  • Systemic corticosteroid treatment within 8 weeks prior to screening